快而精医药

$快而精医药(QGEN)$ IRANNOTICE Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). Accession Number: 0001015820-26-000020  Act: 34  Size: 102 KB 网页链接

$快而精医药(QGEN)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001015820-26-000018  Act: 34  Size: 49 MB 网页链接

$快而精医药(QGEN)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001015820-26-000003  Act: 34  Size: 483 KB 网页链接

$快而精医药(QGEN)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000902219-26-000087  Act: 34  Size: 17 KB 网页链接

$快而精医药(QGEN)$ 包括彭博社在内的媒体报道指出，该公司在收到潜在收购方初步的收购兴趣后，正在评估战略选项，其中可能包括出售。据报道，Qiagen正在与顾问合作，因其监事会正在审查早期阶段的讨论，但无法保证谈判会促成交易。这是继2020年因股东反对导致赛默飞世尔科技(Thermo Fisher)125亿...

$快而精医药(QGEN)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0000876661-26-000016  Act: 34  Size: 4 KB 网页链接

$快而精医药(QGEN)$ 25-NSE/A [Amend] Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0000876661-26-000033  Act: 34  Size: 3 KB 网页链接

$快而精医药(QGEN)$ SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors Accession Number: 0002012383-26-000897  Act: 34  Size: 11 KB 网页链接